- Home
- ARTW vs CMMB Comparison
ARTW vs CMMB Comparison
Compare ARTW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARTW | CMMB |
|---|---|---|
| Founded | 1956 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 9.1M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ARTW | CMMB |
|---|---|---|
| Price | $2.32 | $1.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 39.8K | ★ 68.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 101.67 |
| EPS | ★ 0.20 | 0.04 |
| Revenue | ★ $22,975,408.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $11.60 | $49.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.87 |
| 52 Week High | $4.69 | $3.86 |
Technical Indicators
Market Signals| Indicator | ARTW | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 60.10 |
| Support Level | $2.21 | $1.48 |
| Resistance Level | $2.49 | $2.24 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 19.72 | 91.91 |
Price Performance
Historical ComparisonAbout ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.